We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | |
---|---|---|---|---|---|
-1.00 | -0.07% | 1,459.50 | 1,459.00 | 1,459.50 |
High Price | Low Price | Open Price | Shares Traded | Last Trade |
---|---|---|---|---|
1,462.00 | 1,439.00 | 1,456.00 | 8,609,818 | 16:35:21 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1889 | 12.27 | 60.54B |
Date | Time | Source | Headline |
---|---|---|---|
01/10/2024 | 15:00 | UK RNS | GSK PLC Total Voting Rights |
24/9/2024 | 15:30 | UK RNS | GSK PLC Director/PDMR Shareholding |
24/9/2024 | 09:16 | ALNC | TOP NEWS: GSK celebrates positive EU opinion of liquid Menveo vaccine |
24/9/2024 | 07:00 | UK RNS | GSK PLC Positive EU opinion for GSK liquid Menveo vaccine |
18/9/2024 | 14:00 | ALNC | GSK reaches further two settlements regarding Zantac |
18/9/2024 | 13:20 | UK RNS | GSK PLC Statement: Zantac (ranitidine) litigation |
17/9/2024 | 09:18 | ALNC | GSK says Blenrep combinations accepted for review in Japan |
17/9/2024 | 07:00 | UK RNS | GSK PLC Japan Filing Acceptance: Blenrep Multiple Myeloma |
13/9/2024 | 09:14 | ALNC | GSK myeloma treatment given breakthrough therapy designation in China |
13/9/2024 | 07:00 | UK RNS | GSK PLC China Breakthrough Therapy Designation for Blenrep |
1 Year Gsk Chart |
Intraday Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions